Novel Agents and Combinations for Advanced Renal Cell Carcinoma (RCC)
|
Moores Member and Associate Director of Clinical Science, Rana McKay, MD, discussed the unmet needs and persistent treatment challenges in managing patients with advanced RCC at Targeted Oncology.
|
Mouthwash Test Could Predict Head and Neck Cancer Recurrence
|
Moores Member Joseph Califano, MD led a recent study published in AMA Otolaryngology—Head & Neck Surgery that investigated a new approach to enhance early cancer detection and improve patient outcomes.
|
Future Perspectives on the Treatment of R/R Multiple Myeloma
|
Moores Member Caitlin Costello, MD discussed treating patients with relapsed/refractory multiple myeloma, emphasizing potential opportunities and challenges in the evolving therapeutic landscape at Targeted Oncology.
|
|
|
35th Annual Usha Mahajani Symposium on Molecular Medicine: Physical Forces and the Hallmarks of Cancer
|
Free for Graduate Students and Postdoctoral Fellows
September 6, 2024 | 8:50 a.m. to 5:00 p.m.
Salk Institute, Conrad T. Prebys Auditorium
Attended by 250–300 scientists in academia and industry throughout southern California and beyond, the Usha Mahajani Symposium is held in early September each year and an opportunity for graduate students and postdoctoral fellows to interact with national and international experts in biomedical research related to cancer. This year’s symposium will be co-presented by Moores, with Moores Member Jing Yang, PhD serving as one of the organizers.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Call for Nominations—The Alan T. Waterman Award
|
This award is the nation's highest honor for early-career scientists and engineers that recognizes an outstanding young researcher in any field of science or engineering supported by the National Science Foundation (NSF). The awardee receives a medal and a $1,000,000 grant over 5 years for scientific research or advanced study. Disciplines supported by the NSF are the biological sciences; computer and information science and engineering; engineering; geosciences; mathematical and physical sciences; social, behavioral, and economic sciences; and research on STEM education.
Nominations for the 2025 award will be accepted from July 22 to September 20, 2024.
|
POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology)
|
The POSEIDON program envisions a future in which all cancers are detected
early (while they are still localized) and when curative treatment is far more likely.
POSEIDON will develop first-in-class, at-home, over-the-counter, synthetic-sensor based, multi-cancer-early detection tests for Stage I detection of over 30 solid tumors, using only breath and/or urine samples, which would save millions of lives and eliminate the economic burden of late-stage cancer care.
In-person Proposer's Day | Wednesday, September 4, 2024 (Baltimore, MD)
Registration Deadline | August 27, 2024, 12:00 p.m. EST
|
GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) |
The GLIDE program envisions a future in which doctors will have a therapeutic armamentarium targeting abnormal lymphatic structure and function, expanding the role of the lymphatic system to treat all chronic diseases. GLIDE will develop therapeutic and physical interventions that alleviate, repair, and regenerate irregular or dysfunctional lymphatic vasculature, while including product design and commercialization considerations that favor broad accessibility and adoption by hospitals, healthcare providers, and patients.
Proposer's Day | September 17, 2024 (Hybrid)
Registration Deadline | September 10, 2024, 5:00 p.m. EST
|
|
|
The Researcher Spotlight is designed to help you connect with fellow researchers, gain insights into their diverse projects, and discover the paths that led them to their current roles. Uncover a personal touch to their professional achievements, showcasing the varied perspectives within our cancer research community.
|
Winta Mehtsun, MD, MPH is a surgical oncologist whose practice spans gastric cancer, sarcoma, and general surgical oncology. Dr. Mehtsun enjoys helping her patients through a team-based, multi-disciplinary approach to care, and she is an advocate for patients at all stages of their cancer treatment.
|
|
|
| Salivary CD44 and total protein levels to detect risk for oral and oropharyngeal cancer recurrence: A nonrandomized clinical trial
|
JAMA Otolaryngology—Head & Neck Surgery
|
Joseph Califano, MD (Structural and Functional Genomics) and Karen Messer, PhD (Cancer Control Program)
|
|
|
|
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas
|
Deborah E. Schiff, MD (Hematologic Malignancies)
|
|
|
| Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer—A multicenter SEARCH cohort study
|
Prostate Cancer and Prostatic Diseases
|
Christopher J. Kane, MD (Solid Tumor Therapeutics)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
RLY-2608-101: A First-in-Human Study of Mutant-selective PI3K Inhibitor, RLY2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients With Advanced Breast Cancer
|
PI: Kay Tsuen Yeung, MD, PhD
NCT: NCT05216432
|
|
|
COMMUNITY OUTREACH & ENGAGEMENT (COE) |
Cancer Prevention Education at Grandparents Connection
|
COE presented cancer prevention education and resources to the members of the Grandparents Connection on August 15, 2024. COE looks forward to continuing this collaboration to support efforts in promoting health and well-being.
|
Cancer Prevention 101 with Operation Change
|
COE presented Cancer Prevention 101 to over 30 women from Operation Change. COE looks forward to returning and further supporting cancer screening with subsequent cohorts.
|
|
|
|
